Get the (TELK) Report Here
Trade with Jim Cramer 14 Days FREE
TheStreet highlights 3 stocks that pushed the Drugs industry
Telik (TELK) soared Tuesday after Monday's announcement that the oncology drug development company had entered into a definitive merger agreement with privately held MabVax Therapeutics.
Telik never recovered from hiding the premature deaths of ovarian cancer patients treated with its experimental drug Telcyta in 2007
Carl Icahn's days as an influential activist investor are over after his shameful performance on Yahoo!'s board.
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
A health stock rebound? Plus, my take on Onyx and M&A speculation fun.
Pointing the finger at the FDA isn't a sound investment strategy.
Biogen Idec surges on buyout talk.
This week, updates on Dendreon and Medarex.
Management's behavior on its conference call shows the 80% decline was deserved.
They're heavily shorted and could rise big on good news.
Oculus Innovative Sciences climbs on news of a drug licensing deal.
Regulators probe into why the company waited to report deaths in a cancer drug study.
Rising Treasury yields prompt a setback amid more good economic news. Cody Willard wonders if this is 'as good as it gets.'
Telik tumbles on startling results for its experimental cancer treatment Telcyta.
Alarming results presented at ASCO spur the FDA to act on this Carl Icahn holding.
Cholestech and Digene soar on respective merger news.
Woody Dorsey says the market is set up for another fateful fall.
Major averages approach records, but momentum is waning. Woody Dorsey says it looks like 1987 again.
Johnson & Johnson's rise on better-than-expected earnings boosted health care stocks.
Gene Logic is falling.
He recently added another cancer stock to his portfolio.
PFSweb is rising.
Microsoft and GM help lift the Dow.
CPAC is surging.
Telcyta fails to meet the preset goals of two separate late-stage clinical studies.
He also reports bigger stakes in ImClone and Telik.
The company reports results of the treatment for advanced non-small cell lung cancer.
It's not surprising the stock is down since May, when the company dropped bullish hints about Xyotax.
Genentech's Avastin and ImClone's Erbitux will be a big focus at the huge biotech confab.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.